LimFlow taps ex-Direct Flow GM Rose as CEO
LimFlow said this week that it tapped former Direct Flow Medical VP and GM Daniel Rose as its new chief executive, with former co-founder & CEO Timothy Lenihan transitioning to chief technology officer.
LimFlow is developing a device to create percutaneous venous arterialization in the foot to treat end-stage critical limb ischemia.
Prior to his time with Direct Flow, Rose worked as VP of commercial operations for Sequana Medical AG, developer of implantable pump systems.
“Dan has strong experience in leading medical device businesses and commercializing groundbreaking cardiovascular technologies in Europe and beyond. His experience will be invaluable as we realize our mission to make LimFlow a leading innovator that enables physicians to change the lives of patients living with CLI,” Lenihan said in prepared remarks.
“LimFlow is transforming the treatment of patients facing the loss of a limb due to critical limb ischemia and chronic wounds, a growing clinical need in the face of the diabetes and vascular disease epidemics. I am impressed with their innovative approach to solving this problem and the promising clinical results to date, and I look forward to leading the team to make this the standard of care for treating ‘no option’ CLI,” Rose said in a press release.
Organogenesis taps Cunningham as CFO
Organogenesis said this week that it named Tim Cunningham as its new chief financial officer.
“We are pleased to welcome Tim Cunningham to Organogenesis. His proven leadership and impressive track record of driving operations, managing growth and forming strategic partnerships will be a valuable asset to our company as we continue to grow our commercial operations, expand our product portfolio, and pursue business opportunities in new sectors and markets,” CEO Gary Gillheeney Sr. said in a prepared statement.
Dynatronics picks up new CFO Wirthlin
“David’s deep expertise and experience as both a private and public company CFO brings significant depth to the Dynatronics’ management team. Given David’s extensive background across all of the major disciplines within finance, and his direct experience as a CFO for the past 20 years, I am confident in his ability to lead our finance organization and believe he will be a strong representative to the investor community. I look forward to the ideas and perspectives he will bring to Dynatronics,” chair & CEO Kelvyn Cullimore Jr. said in prepared remarks.
Integer Holdings promotes Friedman to COO
“Jeremy brings tremendous knowledge and experience to this role, having previously served as COO for a subsidiary of one of the world’s largest contract manufacturing companies, where he led the turnaround of a business comprised of 10,000 employees in 17 countries. He is charged with leading our company through the largest acquisition in our history, making us one of the largest medical device outsource manufacturers in the industry. Jeremy will apply his in-depth understanding of lean principles to maximize our integration efforts and strengthen our position in the marketplace,” prez & CEO Thomas Hook said in a prepared statement.
NuVasive picks up Stafslien as GC
NuVasive (NSDQ:NUVA) said this month that it tapped Joan Stafslien as GC, EVP & corporate secretary, joining the company from a position at CareFusion where she served from 2009 until its acquisition by Becton Dickinson (NYSE:BDX) in 2015.
“Joan’s experience spans a broad spectrum of legal areas, including intellectual property, U.S. and International litigation, regulatory compliance, SEC matters and M&A, with extensive experience in the global medical technology sector. Joan’s understanding of complex medical technology companies on high growth trajectories makes her a perfect fit with the strong foundation we have established with our legal team. We continue to invest in building a world-class leadership team to support our growing innovation position in the global spine market,” CEO Greg Lucier said in a press release.
CVRx brings Moore back as US biz dev VP
CVRx earlier this month said it hired Tom Moore, who previously worked for the company, as its new VP of U.S. market development.
“We are really excited to bring Tom back to CVRx in this key leadership role. Tom’s track record in leading the successful enrollment in the Rheos pivotal trial for the treatment of hypertension as well as the Phase II Hope4HF feasibility study for the Barostim NEO device for the treatment of heart failure gives us further confidence in the timely enrollment of the BeAT-HF clinical trial,” prez & CEO Nadim Yared said in a press release.
EnteroMedics makes CEO Gladney chairman as founder Knudson retires
“It is an honor to lead the EnteroMedics Board of Directors at such a pivotal time for the company. EnteroMedics’ commitment to combatting morbid obesity only gets stronger as we press onward towards our goals of both obtaining broad reimbursement coverage for vBloc Therapy and ensuring that this proven option is as widely available as possible. I would like to thank Mark for his service and dedication to the company over the last 14 plus years,” Gladney said in a prepared release.
Farm co-founder Harkins to retire
Farm said last week that its co-founder, president and Farm/Flex GM Jack Harkins is retiring, with Darrin Manke replacing him as GM.
“I’m privileged to have spent the past many years helping Farm grow. We wouldn’t be here without the hundreds of loyal clients we have served over the decades. I’m thankful to have worked alongside not only the most talented people in the industry, but also some of the most considerate – always willing to sacrifice for each other and for our customers. I wish everyone at Farm great things in the future,” Harkins said in a press release.
JenaValve taps former Boston Scientific vet Mirigian
“Greg’s deep delivery catheter and system interaction experience will enable JenaValve to continue to iterate on its transfemoral TAVR system as a world class product offering. He joins us at a time when we are engaged in the clinical trial for CE mark, and we anticipate learning from that trial and incorporating physician feedback to further improve the system for market leadership,” CEO Victoria Carr-Brendel said in a prepared release.
Insulet shuffles the deck
Insulet’s (NSDQ:PODD) this week announced a slew of changes to its personnel roster, naming CEO Patrick Sullivan as chairman, director Dr. Jessica Hopfield as lead independent director, Shacey Petrovic as president & COO and drug-delivery president Daniel Levangie retiring.
“I am pleased the board has appointed Dr. Jessica Hopfield as lead independent director and I thank Dr. John Fallon for his service. As the newly elected chairman, I look forward to working closely with Jessica, John and our fellow board members to continue advancing Insulet’s growth and success. I am also excited to promote Shacey to her new position of president and chief operating officer. Since joining Insulet, she has demonstrated tremendous leadership, overseeing the realignment of our commercial operations, a reset of our product development roadmap and record-breaking commercial results. The further expansion of Shacey’s management responsibilities recognizes her valuable skillset and the meaningful contributions she is making to Insulet’s growth. We believe the company will benefit from a unified approach to developing insulin and non-insulin commercial opportunities for our technology platform and Shacey is the ideal person to oversee this initiative. Dan has been an invaluable member of the Insulet team, leading the drug delivery business through a time of transition and overseeing the development of a long-term strategy for the franchise. His contributions have significantly advanced our drug delivery business and through his roles on the senior leadership team and previously as a member of our board of directors, Dan has helped shape our overall company strategy and organization. On behalf of the entire board and management team, I thank Dan for his commitment to Insulet and wish him all the best,” CEO Sullivan said in prepared remarks.